New drug combo targets tough digestive cancers in key trial
NCT ID NCT05934331
Summary
This study is testing whether a new drug called LM-302, when combined with other cancer treatments, can help control advanced digestive tract cancers that have a specific marker called CLDN18.2. It is for adults whose cancer has continued to grow despite standard first-line treatment. Researchers will measure if the treatment slows cancer progression, shrinks tumors, and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, China
Contact
Conditions
Explore the condition pages connected to this study.